ERBB2 and breast cancer: Tumor-infiltrating immune cells (TICs) are associated with the tumor response to neoadjuvant chemotherapy; these cells are more frequently detected in the HER2+ BC and TNBC subtypes, and have been found to mediate immunotherapy (3–5).